Form PTO-1449 (modified)	Atty. Docket No.: INGN:120US	Serial No.: 10/598,356
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Kerstin MENANDER Robert SOBOL	
	Filing Date: August 24, 2006	Group: ~~Unknown~~ 1632

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0077313	6/20/02	Clayman	514	44	10/1/01
	A2	2002/0006914	1/17/02	Sobol et al.	514	44	1/26/01
	A3	5,747,469	5/5/98	Roth et al.	514	44	4/25/94
	A4	6,017,524	1/25/00	Roth et al.	424	93.2	10/13/92
	A5	6,143,290	11/7/00	Zhang et al.	424	93.2	4/7/94
	A6	6,410,010	6/25/02	Zhang et al.	424	93.2	10/29/93
	A7	6,511,847	1/28/03	Zhang et al.	435	320.1	9/21/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Alexander *et al.*, "Tumor-targeted sensitization to chemotherapy by systemically delivered ligand mediated wtp53 gene therapy," *Proc. Am. Assoc. Can. Res. Ann. Meet.*, 40:596, 1999.
	C2	Browman and Cronin, "Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials," *Semin. Oncol.*, 21:311-319, 1994.
	C3	Buller *et al.*, "Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500," *Cancer Gene Therapy*, 9:567-572, 2000.
	C4	Chang *et al.*, "Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy," *Archives of Otolaryngology Head and Neck Surgery*, 123(5):507-512, 1997.
	C5	Clayman *et al.*, "Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma," *J. Clin. Oncol.*, 16(6):2221-2232, 1998.

25747324.1

EXAMINER:	/Wu-Cheng Winston Shen/	DATE CONSIDERED:	12/03/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.S./

Form PTO-1449 (modified)	Atty. Docket No.: INGN:120US	Serial No.: 10/598,356
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	**Applicant:** Kerstin MENANDER Robert SOBOL	
	Filing Date: August 24, 2006	**Group:** ~~Unknown~~ 1632

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C6	Gurnani *et al.*, "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer," *Cancer Chemother. Pharmacol.*, 44:143-151, 1999.
	C7	Nemunaitis *et al.*, "Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer," *J. Clin. Oncol.*, 18:609-622, 2000.
	C8	Nielsen *et al.*, "Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer," *Clin. Cancer Research*, 4:835-846, 1998.
	C9	Pirollo *et al.*, "p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy," *Oncogene*, 14(14):1735-1746, 1997.
	C10	Roth *et al.*, "Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer," *Nat. Med.*, 2(9):985-991, 1996.

25747324.1

EXAMINER:	/Wu-Cheng Winston Shen/	DATE CONSIDERED:	12/03/2010

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.S./